As one of Iran’s leading knowledge-based companies, Faran Shimi Pharmaceutical Company was established in 2002 with the aim of producing raw materials and narcotic medicines.
The company became operational in 2010, focusing on the production of finished narcotic products and active pharmaceutical ingredients (APIs) as an affiliate of Golrang Pharmaceutical Holding.
Among Faran Shimi’s main activities are the production of specialized medicines such as Migusca, Bosentan, Fampiron, and Metformin, as well as the manufacturing of APIs, including Sitagliptin Phosphate, Empagliflozin, Bosentan Monohydrate, Buprenorphine Hydrochloride, and Apixaban.
The company’s primary objective is to develop new and innovative products aimed at improving people's quality of life and promoting public health.